You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Wideband Tunable Multiferroic Electronics for Advanced RF Systems (1000-277)
SBC: SI2 TECHNOLOGIES, INC Topic: ST13B003SI2 Technologies proposes to design, model, fabricate and transition wideband tunable multiferroic electronics for advanced RF systems including adaptive Radar, software defined radios and other electronic warfare (EW) applications. Combining novel nanost
STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
Multiferroic Materials for RF Applications
SBC: WINCHESTER TECHNOLOGIES LLC Topic: ST13B003Voltage tunable multiferroic materials with strong magnetoelectric coupling provide a unique approach to compact, lightweight and power efficient tunable RF/microwave multiferroic components, such as tunable inductors, filters, phase shifters, etc. The tu
STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent for
SBC: RADIATION MONITORING DEVICES, INC. Topic: N/ADESCRIPTION (provided by applicant): Molecule specific targeting and improving image contrast have been recognized as important research areas in cancer imaging. Goal of cancer diagnosis and prognosis research is to develop new imaging techniques to detect lesions with certainty in early stages so that they can be treated. Developing biomarkers, which will signal the presence and the type of lesio ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells
SBC: ALPHAMED, INC Topic: N/ADESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The selective targeting of alpha-particle emitting radioisotopes for cancer therapy is emerging as an exciting ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Processing Ac-227 sources for lead-212 and radium-223 required by cancer research
SBC: ALPHAMED, INC Topic: N/ADESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Alkylating Vitamin D Derivative
SBC: APHIOS CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Prostate cancer is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US. There are currently no approved therapies for hormone-refractory prostate cancer. Epidemiological studies have demonstrated a strong relationship between incidence of and mortality from various cancers including prostate cancer, exposure to ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Nanotube Reagentless Proteomic Arrays
SBC: EIC LABORATORIES, INC. Topic: N/ADESCRIPTION (provided by applicant): The development of a new technology for reagentless multiplexed determination of protein concentrations in clinical and biological samples is proposed. The proposed approach employs nanotubes with molecular sized openings embedded within a mechanical and chemically robust polymeric membrane. We propose that a microarray may be constructed using these membranes ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health